Expands insurance coverage for pediatric autoimmune neuropsychiatric disorders treatment in Washington.

HB1741 mandates that health plans, excluding those for public employees, cover three monthly courses of intravenous immunoglobulin therapy for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome starting January 1, 2026. This coverage applies if less intensive treatments have failed or were not tolerated, and a pediatric or adult subspecialist and the patient's primary care provider recommend the treatment. The health carrier may require clinical reevaluation every three months.

Expands insurance coverage for pediatric autoimmune neuropsychiatric disorders treatment in Washington.

HB1741 mandates that health plans, excluding those for public employees, cover three monthly courses of intravenous immunoglobulin therapy for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome starting January 1, 2026. This coverage applies if less intensive treatments have failed or were not tolerated, and a pediatric or adult subspecialist and the patient's primary care provider recommend the treatment. The health carrier may require clinical reevaluation every three months.